Personalised Pancreatic Cancer Vaccination Therapy derived from Autologous Tumor Cells and Neoantigens

Project description

Innovative vaccine against pancreatic cancer

Fields of science

• medical and health sciences › clinical medicine › surgery
• medical and health sciences › health sciences › infectious diseases
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• medical and health sciences › basic medicine › immunology › immunotherapy
• medical and health sciences › clinical medicine › oncology › pancreatic cancer

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CYTUVAX BV

Net EU contribution

€ 50 000,00

Address

Oxfordlaan 55
6229 EV Maastricht
Netherlands

Region

Limburg (NL) › Zuid-Limburg

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 21 429,00